Novartis VIBRANT-HD Update

Update From Novartis Regarding VIBRANT-HD Clinical Trials – December 8, 2022 Dear Huntington disease (HD) community, We have received a
Read more
Update From Novartis Regarding VIBRANT-HD Clinical Trials – December 8, 2022 Dear Huntington disease (HD) community, We have received a
Read more
SELECT-HD Trial Update – September 22, 2022 Dear HD Community, We are pleased to announce that Wave Life Sciences has
Read more
ANNOUNCING GENERATION HD2 – 21 September 2022 Dear HD community, We are pleased to share that Roche and Genentech have
Read more
Dear HSC Member, Notice is hereby given that the Annual General Meeting (AGM) of the Members of the Huntington Society
Read more
Update on VIBRANT-HD – Tuesday, August 9, 2022 On Monday, August 8, 2022, Novartis announced their decision to temporarily suspend
Read more
Waterloo, ON, Sept.1, 2021: The Huntington Society of Canada (HSC) is pleased to announce the creation of a stable, long-term
Read more
Today, April 27, was the first day of the annual CHDI Conference. Roche had the opportunity to present about the
Read more
To learn more about the early halt of the Generation-HD1 trial, join HDSA’s webinar on Thursday, April 29th at 12pm
Read more
Dear Huntington disease (HD) community, I have a disappointing update on two HD treatments that were being studied in the
Read more
Dear HSC Community, You may have already heard the sad news about the Roche GENERATION HD1 clinical trial being prematurely
Read more